Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Net Margin (2022 - 2025)

Historic Net Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 349.3%.

  • bioAffinity Technologies' Net Margin fell 2641700.0% to 349.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 217.5%, marking a year-over-year decrease of 1273400.0%. This contributed to the annual value of 96.56% for FY2024, which is 2168500.0% up from last year.
  • Per bioAffinity Technologies' latest filing, its Net Margin stood at 349.3% for Q3 2025, which was down 2641700.0% from 319.88% recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Net Margin peaked at 81.53% during Q1 2024, and registered a low of 427778.96% during Q3 2022.
  • Its 4-year average for Net Margin is 48801.5%, with a median of 334.59% in 2025.
  • The largest annual percentage gain for bioAffinity Technologies' Net Margin in the last 5 years was 2000000000bps (2023), contrasted with its biggest fall of -20742500bps (2023).
  • bioAffinity Technologies' Net Margin (Quarter) stood at 71380.35% in 2022, then soared by 100bps to 107.22% in 2023, then decreased by -25bps to 134.4% in 2024, then crashed by -160bps to 349.3% in 2025.
  • Its Net Margin was 349.3% in Q3 2025, compared to 319.88% in Q2 2025 and 143.53% in Q1 2025.